

**Morgan Stanley Pharmaceutical CEOs Unplugged Conference
January 4 - 6, 2006**

IMPORTANT US REGULATORY DISCLOSURES ON SUBJECT COMPANIES

Important US Regulatory Disclosures on Subject Companies

The following analyst, strategist, or research associate (or a household member) owns securities in a company that he or she covers or recommends in this report: Jami Rubin - Wyeth (common stock), Pfizer Inc (common stock);. Morgan Stanley policy prohibits research analysts, strategists and research associates from investing in securities in their sub industry as defined by the Global Industry Classification Standard ("GICS," which was developed by and is the exclusive property of MSCI and S&P). Analysts may nevertheless own such securities to the extent acquired under a prior policy or in a merger, fund distribution or other involuntary acquisition.

As of November 30, 2005, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in this report: Advanced Medical Optics, Allergan Inc., Bausch & Lomb Inc., Bristol-Myers Squibb, GlaxoSmithKline, Medicis, Merck & Co., Merck KGaA, Mylan Laboratories, Novartis, Pfizer Inc, Sanofi-Aventis, Schering AG, Schering-Plough, Sepracor, Wyeth.

Within the last 12 months, Morgan Stanley managed or co-managed a public offering of securities of Bausch & Lomb Inc., Elan Corp., Merck & Co., Pfizer Inc, Sanofi-Aventis.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Advanced Medical Optics, Allergan Inc., Alcon, AstraZeneca, Bausch & Lomb Inc., Biovail, Bristol-Myers Squibb, Elan Corp., Eli Lilly, Merck & Co., Forest Labs, Merck KGaA, Pfizer Inc, Schering AG, Schering-Plough, Sepracor, Wyeth.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Advanced Medical Optics, Allergan Inc., Alcon, AlphaPharma Inc., AstraZeneca, Barr Pharmaceuticals, Bausch & Lomb Inc., Biovail, Bristol-Myers Squibb, Capio, Cephalon Inc., Chugai Pharmaceutical, Elan Corp., Eli Lilly, Forest Labs, Generale de Sante, GlaxoSmithKline, King Pharmaceuticals, Medicis, Merck & Co., Merck KGaA, Mylan Laboratories, Novartis, Pfizer Inc, Sanofi-Aventis, Schering AG, Schering-Plough, Sepracor, Wyeth.

Within the last 12 months, Morgan Stanley & Co. Incorporated has received compensation for products and services other than investment banking services from Allergan Inc., AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Labs, GlaxoSmithKline, GlaxoSmithKline Pharma, Merck & Co., Novartis, Pfizer Inc, Schering AG, Wyeth.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following

companies covered in this report: Allergan Inc., Advanced Medical Optics, Alcon, Alparma Inc., AstraZeneca, Barr Pharmaceuticals, Bausch & Lomb Inc., Biovail, Bristol-Myers Squibb, Capiro, Cephalon Inc., Chugai Pharmaceutical, Elan Corp., Eli Lilly, Forest Labs, Generale de Sante, GlaxoSmithKline, King Pharmaceuticals, Medicis, Merck & Co., Merck KGaA, Mylan Laboratories, Novartis, Pfizer Inc, Sanofi-Aventis, Schering AG, Schering-Plough, Sepracor, Wyeth.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following companies covered in this report: Allergan Inc., Alparma Inc., AstraZeneca, Bausch & Lomb Inc., Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Forest Labs, GlaxoSmithKline, GlaxoSmithKline Pharma, Merck & Co., Novartis, Pfizer Inc, Schering AG, Schering-Plough, Sepracor, Wyeth.

The research analysts, strategists, or research associates principally responsible for the preparation of this research report have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues.

Morgan Stanley & Co. Incorporated makes a market in the securities of Cephalon Inc., Sepracor.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.